Patents by Inventor Makoto Sunamura

Makoto Sunamura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SALIVARY BIOMARKERS FOR CANCERS, METHODS AND DEVICES FOR ASSAYING THE SAME, AND METHODS FOR DETERMINING SALIVARY BIOMARKERS FOR CANCERS
    Publication number: 20190250164
    Abstract: Salivary biomarker characterized as low-molecular-weight compounds named metabolites or combinations of these biomarkers are used for detecting cancers. The salivary biomarker for cancer can be, for example, a combination of creatinine, N1-acetylspermidine, ?-aminoadipic acid, N-acetylneuraminic acid, and 1,3-diaminopropane. Due to this configuration, the early detection of pancreatic cancer, breast cancer, oral cancer, and the like is possible in a healthy subject even with saliva having large concentration fluctuations.
    Type: Application
    Filed: April 24, 2019
    Publication date: August 15, 2019
    Applicant: SALIVATECH CO. , LTD.
    Inventors: Masahiro SUGIMOTO, Tomoyoshi SOGA, Makoto SUNAMURA
  • SALIVARY BIOMARKERS FOR CANCERS, METHODS AND DEVICES FOR ASSAYING THE SAME, AND METHODS FOR DETERMINING SALIVARY BIOMARKERS FOR CANCERS
    Publication number: 20160282351
    Abstract: Salivary biomarker characterized as low-molecular-weight compounds named metabolites or combinations of these biomarkers are used for detecting cancers. The salivary biomarker for cancer can be, for example, a combination of creatinine, N1-acetylspermidine, ?-aminoadipic acid, N-acetylneuraminic acid, and 1,3-diaminopropane. Due to this configuration, the early detection of pancreatic cancer, breast cancer, oral cancer, and the like is possible in a healthy subject even with saliva having large concentration fluctuations.
    Type: Application
    Filed: October 28, 2014
    Publication date: September 29, 2016
    Applicant: SALIVATECH CO., LTD.
    Inventors: Masahiro SUGIMOTO, Tomoyoshi SOGA, Makoto SUNAMURA
  • Neutralizing monoclonal antibody against human DLL4
    Patent number: 8404233
    Abstract: The present invention provides a binding protein capable of binding to delta-like ligand 4 (DLL4) as well as methods and uses thereof in therapy, diagnosis or imaging. Also provided are fusion proteins and protein conjugates, nucleic acid molecules encoding the binding proteins and methods of preparing binding proteins capable of binding to DLL4.
    Type: Grant
    Filed: May 15, 2008
    Date of Patent: March 26, 2013
    Assignee: Smart Targeting Limited
    Inventors: Makoto Sunamura, Hideo Yagita
  • NEUTRALIZING MONOCLONAL ANTIBODY AGAINST HUMAN DLL4
    Publication number: 20100303812
    Abstract: The present invention provides a binding protein capable of binding to DLL4 as well as methods and uses thereof in therapy, diagnosis or imaging. Also provided are fusion proteins and protein conjugates, nucleic acid molecules encoding the binding proteins and methods of preparing binding proteins capable of binding to DLL4.
    Type: Application
    Filed: May 15, 2008
    Publication date: December 2, 2010
    Applicant: Smart Targeting Limited
    Inventors: Makoto Sunamura, Hideo Yagita